ArticleJournal of Korean medical science2014
Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients.
Article in Journal of Korean medical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Diagnostic pathology · 2016Pooled it
- Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.International journal of clinical and experimental pathology · 2015Pooled it
- Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era.Endocrine-related cancer · 2024Article
- Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report.Medicine · 2024Article
- Follicular cell-derived thyroid carcinomas harboring novel geneticArchives of endocrinology and metabolism · 2024Article
- BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.Journal of clinical medicine · 2023Article
- Expanding the Spectrum ofInternational journal of molecular sciences · 2023Article
- Integrated proteogenomic characterization of medullary thyroid carcinoma.Cell discovery · 2022Article
- Identification of KIT and BRAF mutations in thyroid tissue using next-generation sequencing in an Ecuadorian patient: A case report.Frontiers in oncology · 2022Article
- Clinical and pathologic features for predicting malignancy in thyroid follicular neoplasms.Gland surgery · 2021Article
- Case of aggressive metastatic follicular variant papillary thyroid carcinoma with BRAF K601E and BCORL1 mutations.BMJ case reports · 2020Article
- A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer.Case reports in endocrinology · 2020Article
- Article
- Analysis ofEndocrinology, diabetes & metabolism · 2018Article
- Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.Endocrine pathology · 2017Article
- Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.PloS one · 2017Article
- Frequency and Significance ofFrontiers in endocrinology · 2017Article
- Putative BRAF activating fusion in a medullary thyroid cancer.Cold Spring Harbor molecular case studies · 2016Article
- A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma.Endocrine pathology · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common BRAF mutation in thyroid cancer is c.1799T>A (p.Val600Glu), and other BRAF mutations are rarely reported. We investigated the clinicopathological features of thyroid cancer with rare BRAF mutations. A total of 2,763 patients with thyroid cancer underwent molecular testing by direct DNA sequencing for mutations in BRAF exon 15. Among them, 2,110 (76.4%) had BRAF mutations. The c.1799T>A mutation was found in 2,093 (76.9%) of 2,722 papillary carcinomas and in one of 7 medullary carcinomas. Sixteen cases (0.76%) harbored rare mutation types. Five cases had single-nucleotide substitutions, 5 cases had small in-frame deletion or insertion, and one harbored a two-nucleotide substitution. Of these mutations, 2 were novel (c.1797_1798insGAGACTACA, c.[1799T>A; 1801_1812del]). The c.1801A>G mutation was identified in 4 follicular variant papillary carcinomas and one follicular carcinoma. None of the patients with the c.1801A>G mutation showed extrathyroidal extension or lymph node metastasis. The prevalence of rare BRAF mutations was 0.76% of all BRAF-positive thyroid cancers, and the rare mutations were associated with less aggressive pathologic features. Although BRAF mutations are detected exclusively in papillary carcinoma, they are also found in medullary carcinoma and follicular carcinoma. [Corrected]
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.